Swami B, Lavakusulu D, Devi C S
Curr Med Res Opin. 1977;5(2):152-6. doi: 10.1185/03007997709110156.
Sixty adult patients with symptomatic intestinal amoebiasis and with Entamoeba histolytica present in stools were allocated at random to treatment with tinidazole or metronidazole, both administered in a dose of 2 g once daily for 3 consecutive days. The treatment period was extended in patients with stools positive for Entamoeba histolytica on the day following the last treatment day. Fifty-six patients, 29 on tinidazole and 27 on metronidazole, completed the trial as per the protocol. Twenty-eight patients (96.5%) on tinidazole and 15 (55.5%) on metronidazole were cured. Parasitological cure with partial relief of symptoms was obtained in 1 (3.5%) and 5 (18.5%) patients on tinidazole and metronidazole, respectively. Seven patients (26%) on metronidazole were treatment failures. Treatment had to be extended beyond 3 day in 53% of patients (8/15) on metronidazole as opposed to 11% (3/28) on tinidazole (p less than 0.01). The total number of side-effects, their severity, and the types were more in the metronidazole group. No toxic effects due to either drug were recorded. Tinidazole provided significantly higher cure rates than metronidazole in the treatment of symptomatic intestinal amoebiasis (p less than 0.01), and was better tolerated than metronidazole.
60例有症状的肠道阿米巴病且粪便中检出溶组织内阿米巴的成年患者被随机分配接受替硝唑或甲硝唑治疗，两种药物均每日一次服用2g，连续服用3天。在最后一个治疗日后一天粪便中溶组织内阿米巴仍呈阳性的患者，治疗期延长。56例患者，29例接受替硝唑治疗，27例接受甲硝唑治疗，按方案完成了试验。接受替硝唑治疗的28例患者（96.5%）和接受甲硝唑治疗的15例患者（55.5%）治愈。接受替硝唑和甲硝唑治疗的患者中，分别有1例（3.5%）和5例（18.5%）获得寄生虫学治愈且症状部分缓解。接受甲硝唑治疗的7例患者（26%）治疗失败。甲硝唑组53%（8/15）的患者治疗期不得不延长至3天以上，而替硝唑组为11%（3/28）（p<0.01）。甲硝唑组的副作用总数、严重程度及类型更多。未记录到两种药物引起的毒性作用。在治疗有症状的肠道阿米巴病方面，替硝唑的治愈率显著高于甲硝唑（p<0.01），且耐受性优于甲硝唑。
